2011
Abrahamsen B, Eiken P, Eastell R. Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate. Arch Intern Med 2011 Feb 14.[Epub ahead of print] Abstract
Andrews RE, Shah KM, Wilkinson JM, Gartland A. Effects of cobalt and chromium ions at clinically equivalent concentrations after metal-on-metal hip replacement on human osteoblasts and osteoclasts: Implications for skeletal health. Bone 2011 Jun 13. [Epub ahead of print] Abstract
Boonen S, Van Meirhaeghe J, Bastian L, Cummings SR, Ranstam J, Tillman JB, Eastell R, Talmadge K, Wardlaw D. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Min Res 2011 Jul;26(7):1627-37 Abstract
Coleman RE, McCloskey EV. Bisphosphonates in Oncology. Bone 2011 Feb 11. [Epub ahead of print] Abstract
Dimitri P, Bishop N, Walsh JS, Eastell R. Obesity is a risk factor for fracture in children but is protective against fracture in adults: A paradox. Bone 2011 May [Epub ahead of print]. Abstract
Dimitri P, Wales JK, Bishop N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone 2011, 48(2):189-96 Abstract
Duncan EL, Danoy P, Kemp JP et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet 2011, 7(4):e1001372. Abstract
Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011 Mar; 26(3):530-537. Abstract
Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011 Feb 22 [Epub ahead of print] Abstract
Ellam T, Wilkie M, Chamberlain J, Crossman D, Eastell R, Francis S, Chico TJ. Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2011 Jun [Epub ahead of print] Abstract
Ferrar L, Roux C, Felsenberg D, Glüer CC, Eastell R. Association between incident and baseline vertebral fractures in European women: vertebral fracture assessment in the Osteoporosis and Ultrasound Study. Osteoporos Int 2011, Jul 6. [Epub ahead of print]Abstract
Ferrar L, Roux C, Reid DM, Felsenberg D, Glüer CC, Eastell R. Prevalence of non-fracture short vertebral height is similar in premenopausal and postmenopausal women: the osteoporosis and ultrasound study. Osteoporos Int 2011 May 25. [Epub ahead of print] Abstract
Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int 2011 Mar;22(3):829-37. Epub 2010 Dec 16. Abstract
Fraser LA, Langsetmo L, Berger C et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int 2011, 22(3):829-37. Abstract
Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, Van Hul W et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high bone mass phenotype due to a mutation in Lrp5. J Bone Miner Res 2011 Feb 23. [Epub ahead of print] Abstract
Frost ML, Siddique M, Blake GM et al. Differential effects of teriparatide on regional bone formation using (18) F-fluoride positron emission tomography. J Bone Min Res 2011, 26(5):1002-11. Abstract
Gauthier A, Kanis JA, Martin M, Compston J, Borgström F, Cooper C, McCloskey E et al. Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int 2011 Mar;22(3):771-780. Epub 2010 Aug 11. Abstract
Gregson CL, Steel SA, O'Rourke KP et al. 'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int 2011 Apr 1. [Epub ahead of print] Abstract
Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women. JAMA 2011, 305(8):800-807 Abstract
Johansson H, Clark P, Carlos F, Oden A, McCloskey EV, Kanis JA. Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporos Int 2011 Aug;22(8):2359-64 Abstract
Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011, Jan 13 [Epub ahead of print] Abstract
Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int 2011. [Epub ahead of print] Abstract
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 2011 Mar;22(3):839-47. Epub 2010 Oct 20. Abstract
Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E et al. High fracture probability with FRAX(®) usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 2011 Mar 2. [Epub ahead of print] Abstract
Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA et al. Construction of a FRAX(®) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011 Mar;22(3):817-27. Epub 2010 Dec 16. Abstract
Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR. Effects of antiresorptive treatment on non-vertebral fracture outcomes. J Bone Miner Res 2011, Jun 27 [Epub ahead of print] Abstract
McCloskey E. Preventing osteoporotic fractures in older people. Practitioner 2011, Jan;255(1736):19-22, 2-3. Abstract
McCloskey EV. Bone: Use of FRAX(®) to target BMD in women <65 years of age. Nat Rev Endocrinol 2011 May 31. [Epub ahead of print] Abstract
Smith C, Wright N, Wales J, Mackenzie C, Primhak R, Eastell R, Walsh J. Very low birth weight survivors have reduced peak bone mass and reduced insulin sensitivity. Clin Endocrinol (Oxf) 2011 Jun 2 [Epub ahead of print] Abstract
Southam L, Panoutsopoulou K, Rayner NW, Chapman K, Durrant C, Ferreira T et al. The effect of genome-wide association scan quality control on imputation outcome for common variants. Eur J Hum Genet 2011 Jan 26 [Epub ahead of print] Abstract
Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011 May 24. [Epub ahead of print] Abstract
Wilkinson JM, Little DG. Bisphosphonates in orthopedic applications. Bone 2011, Jan 20 [Epub ahead of print] REVIEW Abstract
2010
Abrahamsen B, Eiken P, Eastell R. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis. J Clin Endocrinol Metab 2010, 95(12):5258-65. Epub 2010 Sep 15 Abstract
Barr R, Macdonald H, Stewart A, McGuigan F, Rogers A, Eastell R, et al. Association between vitamin D receptor gene polymorphisms, falls, balance and muscle power: results from two independent studies (APOSS and OPUS). Osteoporos Int 2010, 21(3):457-66 Abstract
Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362(19):1761-71 Abstract
Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 2010, Oct 12. [Epub ahead of print] Abstract
Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriat Soc 2010, 58(2):292-9 Abstract
Borgström F, Ström O, Kleman M, McCloskey EV, Johansson H, Odén A et al. Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 2010 Jun 8. [Epub ahead of print] Abstract
Czerwinski E, Kanis JA, Osieleniec J, Kumorek A, Milert A, Johansson H et al. Evaluation of FRAX to characterise fracture risk in Poland. Osteoporos Int 2010, Dec 3. [Epub ahead of print] Abstract
Coleman RE, Walsh JS. Bone: causes of low bone mass in breast cancer-time for action? Nat Rev Endocrinol 2010, 6(1):10-2 Abstract REVIEW
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010, 362(8):686-96 Abstract
Czerwinski E, Kanis JA, Osieleniec J, Kumorek A, Milert A, Johansson H et al. Evaluation of FRAX to characterise fracture risk in Poland. Osteoporos Int 2010, Dec 3. [Epub ahead of print] Abstract
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Annals Clin Onc [Epub ahead of print] Abstract
Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2010, Sep 13. [Epub ahead of print] Abstract
Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2010, 21(7):1277-85 Abstract
Eastell R, Newman C, Crossman DC. Cardiovascular disease and bone. Arch Biochem Biophys 2010, 503(1):78-83. Epub 2010 Jun 11 Abstract REVIEW
Eastell R, Rogers A, Ni X, Krege JH. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 2010, Sep 14. [Epub ahead of print] Abstract
Emms NW, Stockley I, Hamer AJ, Wilkinson JM. Long-term outcome of a cementless, hemispherical, press-fit acetabular component. Journal of Bone and Joint Surgery - British Volume 2010, 92(6):856-861 Abstract
Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R, Reid DM et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010, 122(17):1716-24. Abstract
Ferrar L, van der Hee RM, Berry M, Watson C, Miret S, Wilkinson J et al. Effects of calcium-fortified ice cream on markers of bone health. Osteoporosis Int 2010, Dec 18 [Epub ahead of print] Abstract
Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT et al. Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography. J Bone Min Res 2010, Dec 2 [Epub ahead of print] Abstract
Gauthier A, Kanis JA, Martin M, Compston J, Borgström F, Cooper C et al. Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int 2010 Aug 11. [Epub ahead of print] Abstract
Gordon A, Greenfield EM, Eastell R, Kiss-Toth E, Wilkinson JM. Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli. J Orthop Res 2010, 28(9):1127-35 Abstract
Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 2010, 25(3):463-71 Abstract
Jiang G, Luo J, Pollintine P, Dolan P, Adams MA, Eastell R. Vertebral fractures in the elderly may not always be "osteoporotic". Bone 2010, 47(1):111-6 Abstract
Johansson H, Clark P, Carlos F, Oden A, McCloskey EV, Kanis JA. Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporos Int 2010, Dec 21. [Epub ahead of print] Abstract
Johansson H, Odén A, Kanis J, McCloskey EV, Lorentzon M, Ljunggren O et al. Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int 2010, Jun 29. [Epub ahead of print] Abstract
Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM et al. A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int. 2010, 22(2):453-61. Epub 2010 Mar 30 Abstract
Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010, 47(4):729-35 Abstract
Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F. Development and use of FRAX in osteoporosis. Osteoporos Int 2010, 21(Suppl 2):S407-13 Abstract REVIEW
Kerkhof HJM, Meulenbelt I, Akune T, Arden NK, Aromaa A, Bierma-Zeinstra SMA et al. Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis and Cartilage 2010, Nov 6 [Epub ahead pf print] Abstract
Kruger MC, Schollum LM, Kuhn-Sherlock B, Hestiantoro A, Wijanto P, Li-Yu J et al. The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone 2010, 46(3):759-67 Abstract
Lacroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD et al. Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women. J Natl Cancer Inst 2010, 102(22):1706-15 Abstract
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey EV, Kanis JA; Manitoba Bone Density Program. Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. J Bone Miner Res 2010, 25(11):2350-8. Epub 2010 Apr 30 Abstract
Murphy E, Glüer CC, Reid DM, Felsenberg D, Roux C, Eastell R, Williams GR. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 2010, 95(7):3173-81 Abstract
McCloskey EV, Compston J, Cooper C. The US FRAX filter: avoiding confusion or hindering progress? Osteoporos Int 2010, 21(5):885 Abstract LETTER
McCloskey EV. Calculating fracture risk in primary care. Practitioner 2010, 254(1725):7
McCloskey EV, Paterson A, Kanis J, Tähtelä R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 2010, 46(3):558-65 Abstract
Naylor KE, Clowes JA, Finigan J, Paggiosi MA, Peel NF, Eastell R. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 2010, 46(3):592-7 Abstract
Paggiosi MA, Clowes JA, Finigan J, Naylor KE, Peel NF, Eastell R. Performance of Quantitative Ultrasound Measurements of Bone for Monitoring Raloxifene Therapy. J Clin Densitom 2010, 13(4):441-50 Abstract
Paggiosi MA, Glueer CC, Roux C, Reid DM, Felsenberg D, Barkmann R et al. International variation in proximal femur bone mineral density. Osteoporos Int 2010, 22(2):721-9. Epub 2010 Jul 15. Abstract
Panoutsopoulou K, Southam L, Elliott KS, Rayner NW, Zhai G, Beazley C et al. First insights into the genetic architecture of osteoarthritis: interim analysis of the arcOGEN study. Ann Rheum Dis 2010 Dec 21. [Epub ahead of print] Abstract
Rogers A, Glover SJ, Eastell R. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 2010, 45(6):1044-52 Abstract
Southam L, Panoutsopoulou K, Rayner NW, Chapman K, Durrant C, Ferreira T et al. The effect of genome-wide association scan quality control on imputation outcome for common variants. European Journal of Human Genetics (in press)
Stone B, Dockrell D, Bowman C, McCloskey EV. HIV and bone disease. Arch Biochem Biophys 2010, 503(1):66-77 Abstract REVIEW
Ström O, Borgström F, Kleman M, McCloskey EV, Odén A, Johansson H et al. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010, 47(2):430-7 Abstract
Teti A, Eastell R. The central role of the skeleton in chronic diseases. Arch Biochem Biophys 2010, 503(1):1 Abstract EDITORIAL
Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28(6):967-75 Abstract
Walsh JS, Henriksen DB. Feeding and bone. Biochem Biophys 2010, 503(1):11-9 Abstract REVIEW
Walsh JS, Henry YM, Fatayerji D, Eastell R. Hormonal determinants of bone turnover before and after attainment of peak bone mass. Clin Endocrinol (Oxf) 2010, 72(3):320-7 Abstract
Walsh JS, Eastell R, Peel NF. Depot medroxyprogesterone acetate use after peakbone mass is associated with increased bone turnover but no decrease in bone mineral density. Fertil Steril 2010, 93(3):691-701 Abstract
2009
Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Min Res 2009, 24(6):1095-102 Abstract
Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789; Abstract [Comment on N Engl J Med. 2009, 360(1):89-90]
Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE et al. Bone turnover markers, hip bone loss and fracture in older men: the MrOS Study. J Bone Min Res 2009, 24(12):2032-8 Abstract
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-65 Abstract
Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Min Res 2009, 24(9):1544-51 Abstract
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009, 94(9):3215-25 Abstract
Eastell R, Ebeling PR. Bone turnover markers: a key tool for understanding osteoporosis. Osteoporos Int 2009, 20(Suppl 3):S237-8 Abstract PERSONAL VIEW
Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Min Res 2009, 24(4):726-36 Abstract
Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J et al. Rapid and Robust Biochemical Response to Teriparatide Therapy for Osteoporosis. Bone 2009, 45(6):1053-8 Abstract
Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S et al. Establishing a Reference Range for Bone Turnover Markers in 637 healthy, Young, Pre-menopausal Women from UK, France, Belgium and the USA. J Bone Min Res 2009, 24(3):389-97 Abstract
Johansson H, Kanis JA, Oden A, Johnell O, McCloskey EV. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009, 20(10):1675-82 Abstract
Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey EV.
FRAX and its applications to clinical practice. Bone 2009, 44(5):734-43 Abstract
Kanis JA, Johansson H, Oden A, McCloskey EV. Basedoxifene reduces clinical and vertebral fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009, 44(6):1049-54 Abstract
McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009, 20(5):811-7 Abstract
Walsh JS, Henry YM, Fatayerji D, Eastell R. Lumbar spine peak bone mass and bone turnover in men and women: longitudinal study. Osteoporos Int 2009, 20(3):355-62 Abstract
Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 2009, 373(9668):1016-24 Abstract
Yang L, Peel N, Clowes JA, McCloskey EV, Eastell R. Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Min Res 2009, 24(1):33-42 Abstract
